GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (OTCPK:MBXBF) » Definitions » ROE % Adjusted to Book Value

MBXBF (Microbix Biosystems) ROE % Adjusted to Book Value : 6.13% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Microbix Biosystems ROE % Adjusted to Book Value?

Microbix Biosystems's ROE % for the quarter that ended in Dec. 2024 was 11.70%. Microbix Biosystems's PB Ratio for the quarter that ended in Dec. 2024 was 1.91. Microbix Biosystems's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 6.13%.


Microbix Biosystems ROE % Adjusted to Book Value Historical Data

The historical data trend for Microbix Biosystems's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems ROE % Adjusted to Book Value Chart

Microbix Biosystems Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.67 6.15 2.91 -0.09 8.06

Microbix Biosystems Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.23 2.93 2.38 3.81 6.13

Competitive Comparison of Microbix Biosystems's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Microbix Biosystems's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's ROE % Adjusted to Book Value falls into.



Microbix Biosystems ROE % Adjusted to Book Value Calculation

Microbix Biosystems's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=13.30% / 1.65
=8.06%

Microbix Biosystems's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.70% / 1.91
=6.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and; Development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.